- Home
- APRE vs ALZN Comparison
APRE vs ALZN Comparison
Compare APRE & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- ALZN
- Stock Information
- Founded
- APRE 2006
- ALZN 2016
- Country
- APRE United States
- ALZN United States
- Employees
- APRE N/A
- ALZN N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- APRE Health Care
- ALZN Health Care
- Exchange
- APRE Nasdaq
- ALZN Nasdaq
- Market Cap
- APRE 8.3M
- ALZN 8.2M
- IPO Year
- APRE 2019
- ALZN 2021
- Fundamental
- Price
- APRE $1.47
- ALZN $2.51
- Analyst Decision
- APRE Strong Buy
- ALZN Strong Buy
- Analyst Count
- APRE 1
- ALZN 1
- Target Price
- APRE $20.00
- ALZN $42.00
- AVG Volume (30 Days)
- APRE 40.4K
- ALZN 156.7K
- Earning Date
- APRE 11-06-2025
- ALZN 09-10-2025
- Dividend Yield
- APRE N/A
- ALZN N/A
- EPS Growth
- APRE N/A
- ALZN N/A
- EPS
- APRE N/A
- ALZN N/A
- Revenue
- APRE $841,012.00
- ALZN N/A
- Revenue This Year
- APRE N/A
- ALZN N/A
- Revenue Next Year
- APRE N/A
- ALZN N/A
- P/E Ratio
- APRE N/A
- ALZN N/A
- Revenue Growth
- APRE N/A
- ALZN N/A
- 52 Week Low
- APRE $1.37
- ALZN $2.06
- 52 Week High
- APRE $5.01
- ALZN $17.10
- Technical
- Relative Strength Index (RSI)
- APRE 45.12
- ALZN 54.71
- Support Level
- APRE $1.46
- ALZN $2.33
- Resistance Level
- APRE $1.57
- ALZN $2.55
- Average True Range (ATR)
- APRE 0.08
- ALZN 0.11
- MACD
- APRE 0.01
- ALZN 0.02
- Stochastic Oscillator
- APRE 54.45
- ALZN 67.19
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.